Research Topics
Species | Magnus SjogrenSummaryAffiliation: Sahlgrenska University Hospital Country: Sweden Publications
| Collaborators
|
Detail Information
Publications
Cytoskeleton proteins in CSF distinguish frontotemporal dementia from ADM Sjogren
Institute of Clinical Neuroscience, Goteborg University, Sweden
Neurology 54:1960-4. 2000..Both proteins have been implicated in the pathophysiology of FTD...- Advances in the detection of Alzheimer's disease-use of cerebrospinal fluid biomarkersMagnus Sjogren
Institute of Clinical Neuroscience, Goteborg University, SE 431 80, Goteborg, Sweden
Clin Chim Acta 332:1-10. 2003..It increases if P-tau is added. An increasing number of studies suggest that supplementary use of these CSF markers, preferably in combination, adds to the accuracy of an AD diagnosis... - Treatment with simvastatin in patients with Alzheimer's disease lowers both alpha- and beta-cleaved amyloid precursor proteinMagnus Sjogren
Institute of Clinical Neuroscience, Goteborg University, Sahlgrenska University Hospital Molndal, SE 431 80 Molndal, Sweden
Dement Geriatr Cogn Disord 16:25-30. 2003..The ADAS-cog score was slightly increased (p < 0.05). The results suggest that simvastatin acts directly on the processing of APP by inhibiting both the alpha- and the beta-secretase pathways... - Cognition-enhancing effect of vagus nerve stimulation in patients with Alzheimer's disease: a pilot studyMagnus J C Sjögren
Institute of Clinical Neuroscience, Goteborg University, Molndal, Sweden
J Clin Psychiatry 63:972-80. 2002..The purpose of the present pilot study was to investigate the effect of VNS on cognition in patients with Alzheimer's disease... - Biological correlates of clinical subgroups of Alzheimer's diseaseMagnus Sjogren
Institute of Clinical Neuroscience, Goteborg University, Goteborg, Sweden
Dement Geriatr Cogn Disord 14:191-7. 2002..For instance, a decreased CSF level of HVA (p < 0.001) was specific to AD type I and decreased rCBF (p < 0.05 to <0.001) in three particular regions was specific to AD type II... - [A new putative principle for diagnosis of Creutzfeldt-Jakob disease]Magnus Sjogren
Sahlgrenska Universitetssjukhuset Mölndal
Lakartidningen 99:2382-4. 2002..This change is detectable early in the course of the disease also in tissues outside the central nervous system, for instance blood... - Neurofilament protein in cerebrospinal fluid: a marker of white matter changesM Sjogren
Institute of Clinical Neuroscience, Goteborg University, Goteborg, Sweden
J Neurosci Res 66:510-6. 2001..Because NFL is located mainly in large myelinated axons, increased CSF NFL in individuals with WMC probably reflects axonal degeneration... - Low cerebrospinal fluid beta-amyloid 42 in patients with acute bacterial meningitis and normalization after treatmentM Sjogren
Institute of Clinical Neuroscience, Goteborg University, Sahlgrenska University Hospital, Molndal, SE 431 80 Molndal, Sweden
Neurosci Lett 314:33-6. 2001..Our findings suggest that the reduction in CSF-A beta 42 found in bacterial meningitis is not a direct consequence of the inflammatory process. The cause may be disturbance of the clearance of A beta 42 from the brain... - Frontotemporal dementia can be distinguished from Alzheimer's disease and subcortical white matter dementia by an anterior-to-posterior rCBF-SPET ratioM Sjogren
Institute of Clinical Neuroscience, Goteborg University, Goteborg, Sweden
Dement Geriatr Cogn Disord 11:275-85. 2000..6%. CT/MRI was found to be helpful in the differential diagnosis between FTD and SWD. In FTD patients, the mesial superior frontal gyrus, near the polus frontalis, was found to be the region with the most reduced rCBF values... - CSF levels of tau, beta-amyloid(1-42) and GAP-43 in frontotemporal dementia, other types of dementia and normal agingM Sjogren
Institute of Clinical Neuroscience, Göbteborg University, Sahlgrenska University Hospital, Molndal, Sweden
J Neural Transm 107:563-79. 2000..In SWD, decreased levels of CSF-beta-amyloid(1-42) suggest concomitant involvement of vascular and amyloid protein mechanisms... 
Both total and phosphorylated tau are increased in Alzheimer's diseaseM Sjogren
Institute of Clinical Neuroscience, Goteborg University, Sahlgrenska University Hospital SE 431 80 Mölndal, Sweden
J Neurol Neurosurg Psychiatry 70:624-30. 2001..As CSF tau protein is increased after stroke, tau may also be implicated in the pathophysiology of vascular dementia, of which subcortical arteriosclerotic encephalopathy (SAE) is a putative subtype...- Tacrine and rate of progression in Alzheimer's disease--relation to ApoE allele genotypeM Sjogren
Institute of Clinical Neuroscience, Goteborg University, Sahlgrenska University Hospital Molndal, Sweden
J Neural Transm 108:451-8. 2001..The results primarily suggest a faster rate of decline in the ApoE4 AD compared to the ApoE2-3, but may also reflect that ApoE epsilon4 genotype inheritance is a negative predictor of treatment effect of tacrine in AD patients... - Tau and Abeta42 in cerebrospinal fluid from healthy adults 21-93 years of age: establishment of reference valuesM Sjogren
Institute of Clinical Neuroscience, Psychiatry Section, Goteborg University, SE 431 80 Molndal, Sweden
Clin Chem 47:1776-81. 2001..For the introduction of these assays in clinical practice, adequate reference values are of importance... - Measurement of alpha- and beta-secretase cleaved amyloid precursor protein in cerebrospinal fluid from Alzheimer patientsAnnika Olsson
Institute of Clinical Neuroscience, Experimental Neuroscience Section, Goteborg University, Sahlgrenska University Hospital, Molndal, Sweden
Exp Neurol 183:74-80. 2003..Neither the levels of CSF-beta-sAPP nor CSF-Abeta(42) differed when comparing ApoE4 allele-positive with allele-negative individuals... - Decreased CSF-beta-amyloid 42 in Alzheimer's disease and amyotrophic lateral sclerosis may reflect mismetabolism of beta-amyloid induced by disparate mechanismsMagnus Sjogren
Institute of Clinical Neuroscience, Goteborg University, Sahlgrenska University Hospital, Molndal, Sweden
Dement Geriatr Cogn Disord 13:112-8. 2002..Furthermore, decreased CSF-Abeta42 levels may be common in neurodegenerative disorders possibly reflecting changes in the metabolism of beta-amyloid or axonal degeneration... - Depressive symptoms and white matter changes in patients with dementiaKarin Lind
Institute of Clinical Neuroscience, Goteborg University, Sweden
Int J Geriatr Psychiatry 21:119-25. 2006..The aim of the present study was to investigate if depressive symptoms in demented patients are associated with white matter changes (WMCs) in the brain... - Decreased cerebrospinal fluid acetylcholinesterase in patients with subcortical ischemic vascular dementiaAnders Wallin
Institute of Clinical Neuroscience, Sahlgrenska University Hospital, Molndal, Sweden
Dement Geriatr Cogn Disord 16:200-7. 2003..01) and FTD groups (p < 0.05). No influence of ApoE epsilon4 allele possession on CSF-AChE activity was found. It is suggested that abnormal CSF-AChE activity in patients with SVD reflects a disturbance in the cholinergic system... 
The pattern of cognitive symptoms predicts time to dementia onsetSimona Sacuiu
Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, Sahlgrenska Academy, University of Gothenburg, Molndal, Sweden
Alzheimers Dement 5:199-206. 2009..Our objective was to investigate whether different patterns of cognitive symptoms at ages 70, 75, and 79 years predict short-term (< or =5 years) and long-term (>5 years) dementia onset...- Increased intrathecal levels of the angiogenic factors VEGF and TGF-beta in Alzheimer's disease and vascular dementiaElisabeth Tarkowski
Department of Rheumatology, University of Goteborg, Goteborg, Sweden
Neurobiol Aging 23:237-43. 2002..In addition, we show in AD and VAD an intrathecal production of TGF-beta, a cytokine exerting on one hand anti-inflammatory and angiogenic properties, but on the other promoting amyloidogenesis... - The use of proteomics in biomarker discovery in neurodegenerative diseasesPia Davidsson
Discovery Medicine Molecular Sciences, AstraZeneca R and D, Molndal, Sweden
Dis Markers 21:81-92. 2005.... - Proteome studies of CSF in AD patientsPia Davidsson
Discovery Medicine Molecular Pharmacology, AstraZeneca R and D, Molndal, SE 431 83 Molndal, Sweden
Mech Ageing Dev 127:133-7. 2006..Several studies show that the use of a panel of biomarkers derived from proteomic analysis is an advantageous way to distinguish AD from normal, and other dementia subjects... - Negative neurofilament light and tau immunostaining in frontotemporal dementiaMagnus Sjogren
Department of Neuropsychiatry, Sahlgrenska University Hospital, Molndal, Sweden
Dement Geriatr Cogn Disord 17:346-9. 2004..These findings regarding NFL and tau staining may be useful in the differential diagnosis of FLD and AD... - Objective measurement of the alertness level in dementiaAke Edman
Institute of Clinical Neuroscience, Section of Psychiatry, Goteborg University, Sahlgrenska University Hospital, Molndal, Sweden
Dement Geriatr Cogn Disord 15:212-7. 2003..The intensity of this decrease was proportional to the degree of the dementia. The alertness disturbance was found to be particularly associated with the parietal brain syndrome... - Studies of the pathophysiological mechanisms in frontotemporal dementia by proteome analysis of CSF proteinsPia Davidsson
Department of Clinical Neuroscience, Experimental Neuroscience Section, Goteborg University, Sahlgrenska University Hospital, Molndal, Sweden
Brain Res Mol Brain Res 109:128-33. 2002.... - Classification and subtypes of vascular dementiaAnders Wallin
Goteborg University, Institute of Clinical Neuroscience, Sahlgrenska University Hospital, Molndal, Sweden
Int Psychogeriatr 15:27-37. 2003..Subcortical VaD has a relatively homogeneous clinical picture for which detailed criteria are suggested. AD + VaD is more difficult to identify but is possible, sometimes with the aid of neuroimaging and/or biological markers...